TRAMETINIB DRIVES T CELL-DEPENDENT CONTROL OF K-RAS-MUTATED TUMORS BY INHIBITING PATHOLOGICAL MYELOPOIESIS

Targeted therapies elicit seemingly paradoxical and poorly understood effects on tumor immunity. Here we show that the MEK inhibitor trametinib abrogates cytokine-driven expansion of monocytic myeloid-derived suppressor cells (mMDSC) from human or mouse myeloid progenitors. MEK inhibition also reduc...

Full description

Saved in:
Bibliographic Details
Published in:Cancer Res
Main Authors: Allegrezza, Michael J., Rutkowski, Melanie R., Stephen, Tom L., Svoronos, Nikolaos, Perales-Puchalt, Alfredo, Nguyen, Jenny M., Payne, Kyle K., Singhal, Sunil, Eruslanov, Evgeniy B., Tchou, Julia, Conejo-Garcia, Jose R.
Format: Artigo
Language:Inglês
Published: 2016
Subjects:
Article
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC5094194/
https://ncbi.nlm.nih.gov/pubmed/27803104
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/0008-5472.CAN-16-1308
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items